Please use this identifier to cite or link to this item: https://hdl.handle.net/1/2040
Title: An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as children with ALL
Authors: Wylie, Brenton ;Greenwood, M.;Trahair, T.;Sutton, R.;Osborn, M.P.;Kwan, J.;Mapp, S.;Howman, R.;Anazodo, A.;D'Rozario, J.;Hertzberg, M.;Irving, I.;Yeung, D.T.;Coyle, L.;Jager, A.;Engeler, D.M.;Venn, N.C.;Frampton, C.;Wei, A.H.;Bradstock, K.F.;Dalla-Pozza, L.
Affliation: Central Coast Local Health District
Gosford Hospital
Issue Date: Oct-2021
Source: 5(24):5574-5583
Journal title: Blood Advances
Department: Haematology
Medical Oncology
Abstract: Pediatric regimens have improved outcomes in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL). However, results remain inferior to children with ALL. The ALLG ALL06 study (anzctr.org.au/ACTRN12611000814976) was designed to assess whether a pediatric ALL regimen (ANZCHOG Study 8) could be administered to patients aged 15-39 years in a comparable time frame to children as assessed by the proportion of patients completing induction/consolidation and commencing the next phase of therapy - protocol M or high risk (HR) treatment - by day 94. Minimal residual disease (MRD) response stratified patients to HR treatment and transplantation. From 2012 to 2018, 86 patients were enrolled; 82 were eligible. Median age was 22 (range, 16-38) years. Induction/consolidation was equally deliverable in ALL06 as in Study 8. In ALL06, 41.5% (95%CI, 30.7-52.9) commenced protocol M or HR therapy by day 94 vs 39.3% in Study 8 (p=0.77). Median time to protocol M/HR treatment was 96 (IQR, 87.5-103) days in ALL06 vs 98 days in Study 8 (p=0.80). Induction mortality was 3.6%. With median follow up of 44 (1-96) months, estimated 3-year disease free survival (DFS) was 72.8% (95%CI, 62.8-82.7) and estimated 3-year overall survival (OS) was 74.9% (95%CI, 65.3-84.5%). End induction/consolidation MRD negativity rate was 58.6%. Body mass index (BMI) ≥30 and day 79 MRD positivity were associated with poorer DFS and OS. Pediatric therapy was safe and as deliverable in AYA patients as children with ALL. Intolerance of pediatric ALL induction/consolidation is not a major contributor to inferior outcomes in AYA ALL.
URI: https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/2040
DOI: 10.1182/bloodadvances.2021005576
Pubmed: https://pubmed.ncbi.nlm.nih.gov/34662896/
ISSN: 2473-9529
Publicaton type: Journal Article
Keywords: Leukaemia
Leukemia
Pediatrics
Paediatrics
Appears in Collections:Obstetrics / Paediatrics

Show full item record

Page view(s)

14
checked on Jan 28, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.